Project 1: Mechanisms of Disease Progression
项目1:疾病进展机制
基本信息
- 批准号:10339373
- 负责人:
- 金额:$ 95.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-02-12 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AfricaBacillusBacteriaBloodCandidate Disease GeneCell NucleusCellsClinicalClinical TrialsDataData SetDiseaseDisease ProgressionDoseEarly treatmentEicosanoidsEpidemiologyExhibitsGene Expression ProfileGeneticGenomicsHealthHeterogeneityHumanImmuneImmune responseIndividualInfectionInflammation MediatorsInflammatory ResponseInhalationLinkLungMachine LearningMeasurementMediatingMetadataModelingMolecularMonitorMouse StrainsMusMutationMycobacterium tuberculosisOrthologous GeneOutcomePathogenicityPathway interactionsPhenotypePhysiologicalPopulationProcessPublishingResearch InstituteRiskRoleShapesSiteSymptomsSystemSystems BiologyTestingTimeTranslatingTuberculosisVaccinesWaterWorkaerosolizedbasechemokineclinical phenotypecytokinedisease heterogeneitygenetic associationgenetic manipulationhuman diseaseimmune functionimprovedin vivoinsightlatent infectionmolecular modelingmouse modelmultiple omicsnonhuman primatenovelpredictive signaturepredictive testpreventprogramsresponsetranscriptomics
项目摘要
Abstract – Project 1
Human Mtb infection results in a large variety of clinical outcomes, ranging from bacterial eradication, to control
and latent infection, to progression and active disease with a range of clinical phenotypes. We recently
discovered a blood transcriptional signature that predicts TB risk in Mtb-exposed individuals up to 18 months
before they exhibit clinical symptoms, a landmark contribution to the field. Still, the mechanisms that underlie
TB disease progression remain poorly understood, in large part because the key immune responses within the
human lung cannot be readily monitored. Furthermore, TB is a highly heterogeneous disease in which
individuals progress to active disease due to a variety of mechanisms. In this project, we will conduct a
comprehensive, multi-scale integration of transcriptomic, cytokine, chemokine and eicosanoid profiles from
lung and blood during Mtb infection in order to identify and model molecular mechanisms and pathways that
determine the outcome of infection. First, we will use multiple experimental strategies to recapitulate the
heterogeneity of human Mtb infection in the mouse. These include a novel “ultra low dose” (ULD) infection
model that we have pioneered in which mice are infected with 1-3 bacteria and subsequently exhibit a broad
range of outcomes, ranging from immune control to progression. We will also employ mice from the
Collaborative Cross project that have demonstrated extreme TB phenotypes and Mtb strains that span a range
of pathogenicity. Second, we will interrogate and model the host-Mtb interaction in these mouse models using
a variety of systems biology approaches in order to uncover the molecular regulators, pathways, and networks
in pulmonary innate and adaptive immune cells. We will test the predicted role of critical regulatory molecules
by genetically perturbing them in vivo and examining the impact on control of Mtb infection. We will also apply
machine-learning approaches to define multi-omic blood based signatures in mice that predict TB progression.
In our preliminary work, we have defined an early blood-based signature that predicts the late-time bacterial
burdens in ULD-infected mice. We will correlate this signature with systems-level measurements of immune
function in the lung to uncover mechanisms of Mtb control. Third, we will translate these findings to human
disease. Through the Africa Health Research Institute, we will leverage a large-scale program that will obtain
genomic sequence data as well as associated epidemiological and clinical metadata on 50,000 individuals
living in a TB-endemic region. We will conduct a candidate gene genetic association analysis to validate
regulatory molecules identified in mice to determine whether mutations in human orthologs are associated with
altered risk of TB. In addition, we will use several existing non-human primate and human datasets to refine
the blood based multi-omic progression signatures defined in mice and test their ability to predict TB
progression in humans.
摘要-项目1
人类结核分枝杆菌感染导致各种各样的临床结果,从细菌根除到控制结核分枝杆菌感染,
和潜伏感染,进展和活动性疾病与一系列临床表型。我们最近
发现了一种血液转录特征,可预测结核病暴露个体长达18个月的结核病风险
在他们表现出临床症状之前,这是该领域的一个里程碑式的贡献。尽管如此,
结核病的进展仍然知之甚少,这在很大程度上是因为结核病患者体内的关键免疫反应,
不能容易地监测人肺。此外,结核病是一种高度异质性的疾病,
个体由于多种机制而进展为活动性疾病。在这个项目中,我们将进行一个
转录组、细胞因子、趋化因子和类花生酸谱的全面、多尺度整合,
肺和血液,以确定和模拟分子机制和途径,
决定感染的结果。首先,我们将使用多种实验策略来概括
小鼠中人Mtb感染的异质性。其中包括一种新型的“超低剂量”(ULD)感染
我们开创的模型中,小鼠感染1-3种细菌,随后表现出广泛的
从免疫控制到疾病进展。我们还将使用来自
协作交叉项目已证明极端结核表型和跨越一系列的结核分枝杆菌菌株
致病性。第二,我们将使用以下方法在这些小鼠模型中询问和建模宿主-Mtb相互作用:
各种系统生物学方法,以揭示分子调节因子,途径和网络
在肺部先天性和适应性免疫细胞中。我们将测试关键调节分子的预测作用,
通过在体内对其进行遗传干扰并检查对Mtb感染控制的影响。我们还将应用
机器学习方法在小鼠中定义基于血液的多组学特征,以预测TB进展。
在我们的初步工作中,我们已经确定了一个早期的基于血液的签名,可以预测晚期细菌
ULD感染小鼠的负担。我们将把这个特征与免疫系统水平的测量相关联,
在肺中发挥作用,以揭示结核病控制机制。第三,我们将把这些发现转化为人类
疾病通过非洲健康研究所,我们将利用一个大规模的计划,
50,000人的基因组序列数据以及相关的流行病学和临床元数据
生活在结核病流行地区我们将进行候选基因遗传关联分析,
在小鼠中鉴定的调节分子,以确定人类直系同源物中的突变是否与
改变了患结核病的风险。此外,我们将使用几个现有的非人类灵长类动物和人类数据集来完善
在小鼠中定义的基于血液的多组学进展特征,并测试其预测TB的能力
人类的进步。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALAN A ADEREM其他文献
ALAN A ADEREM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALAN A ADEREM', 18)}}的其他基金
Omics for TB: Response to Infection and Treatment
结核病组学:对感染和治疗的反应
- 批准号:
10339369 - 财政年份:2018
- 资助金额:
$ 95.12万 - 项目类别:
相似国自然基金
猪源益生菌Bacillus licheniformis PGM584缓解仔猪断奶腹泻的机制研究
- 批准号:2025JJ50141
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Bacillus subtilis 细胞传感器介导的肠道环境中结直肠癌相关生物标志物的动态检测策略
- 批准号:82372355
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
枯草芽孢杆菌Bacillus subtilis T5高效制备纳米硒及其合成机制研究
- 批准号:n/a
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
生物炭载解化感物质促生菌Bacillus cereus WL08缓解半夏连作障碍的机制研究
- 批准号:32360023
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
工程化Bacillus clausii胞外囊泡口服递送PD-L1自阻断质粒协同抗胰腺癌作用研究
- 批准号:82373277
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
CRISPR/CasΦ介导的Bacillus subtilis基因组精简重排进化与生理机制解析
- 批准号:32300064
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
芽孢杆菌Bacillus sp.E044对羊肚菌主要病害-镰刀菌病生物防治的作用机制
- 批准号:22ZR1442500
- 批准年份:2022
- 资助金额:0.0 万元
- 项目类别:省市级项目
Bacillus sp. DT2与凤眼莲根际生物膜对四环素的协同降解机制研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
基于Bacillus safensis的聚乳酸降解酶催化机制解析与分子改造
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
施用锰肥提高生防细菌Bacillus cereus 0-9在小麦根际定殖的作用机制
- 批准号:32172488
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:面上项目
相似海外基金
Constitutive oxalate-biodegrading Bacillus subtilis for kidney stones
用于肾结石的组成型草酸盐生物降解枯草芽孢杆菌
- 批准号:
10740242 - 财政年份:2023
- 资助金额:
$ 95.12万 - 项目类别:
Identifying novel resistance mechanisms in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)
识别卡介苗 (BCG) 治疗的非肌层浸润性膀胱癌的新耐药机制
- 批准号:
10742368 - 财政年份:2023
- 资助金额:
$ 95.12万 - 项目类别:
Chemical Biology of Nitroxyl (HNO) in Bacillus Subtilis
枯草芽孢杆菌中硝酰基 (HNO) 的化学生物学
- 批准号:
10730746 - 财政年份:2023
- 资助金额:
$ 95.12万 - 项目类别:
Molecular Mechanisms of Y-Family Translesion Polymerase Activity in Bacillus subtilis
枯草芽孢杆菌 Y 家族跨损伤聚合酶活性的分子机制
- 批准号:
10730396 - 财政年份:2023
- 资助金额:
$ 95.12万 - 项目类别:
Mechanisms and regulation of replication, the cell cycle, gene expression, and horizontal gene transfer in prokaryotes, focusing on Bacillus subtilis
原核生物复制、细胞周期、基因表达和水平基因转移的机制和调控,重点关注枯草芽孢杆菌
- 批准号:
10792219 - 财政年份:2023
- 资助金额:
$ 95.12万 - 项目类别:
Discovery and functional analysis of novel selective cancer cell-damaging proteins produced by Bacillus thuringiensis.
苏云金芽孢杆菌产生的新型选择性癌细胞损伤蛋白的发现和功能分析。
- 批准号:
23K05020 - 财政年份:2023
- 资助金额:
$ 95.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms and regulation of replication, the cell cycle, gene expression, and horizontal gene transfer in prokaryotes, focusing on Bacillus subtilis.
原核生物复制、细胞周期、基因表达和水平基因转移的机制和调控,重点关注枯草芽孢杆菌。
- 批准号:
10552390 - 财政年份:2023
- 资助金额:
$ 95.12万 - 项目类别:
Interrogating laboratory-adapted strains of Bacillus subtilis to elucidate the selective pressures of laboratory conditions on multicellular bacterial behaviors
研究实验室适应的枯草芽孢杆菌菌株,以阐明实验室条件对多细胞细菌行为的选择压力
- 批准号:
10577916 - 财政年份:2023
- 资助金额:
$ 95.12万 - 项目类别:
YloC, a new ribonuclease of Bacillus subtilis
YloC,枯草芽孢杆菌的新型核糖核酸酶
- 批准号:
10736779 - 财政年份:2023
- 资助金额:
$ 95.12万 - 项目类别:
Bacillus Subtilis Chaperone/protease Mechanisms In Metabolic Shutdown
枯草芽孢杆菌伴侣/蛋白酶代谢关闭机制
- 批准号:
BB/X001415/1 - 财政年份:2023
- 资助金额:
$ 95.12万 - 项目类别:
Research Grant